1. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women;Block;Pediatrics,2006
2. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years;Petäjä;J. Adolesc. Health,2009
3. Palefsky J, Giuliano A. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. Presented at the 2008 Conference of the European Research Organization on Genital Infection and Neoplasia (EUROGIN); 2008 Nov 12–15; Nice, France. Abstract PS 1-3a.
4. Giuliano A, Palefsky J. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. Presented at the 2008 Conference of the European Research Organization on Genital Infection and Neoplasia (EUROGIN); 2008 Nov 12–15; Nice, France. Abstract SS 19-7a.
5. US Food and Drug Administration. October 16, 2009 Approval Letter—Gardasil. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186991.htm [accessed 2009 Nov 10].